NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders, including bipolar depression and suicidal ideation, as well as acute respiratory conditions. The company became publicly traded through its merger with Big Rock Partners Acquisition Corp. (Nasdaq: BRPA), a blank-check vehicle sponsored by Big Rock Partners, LLC that completed its IPO in 2020. The de-SPAC business combination closed in October 2021, transitioning NRX into a listed CNS and specialty pharma company. An 8-K disclosure was filed in March 2024, continuing the company's regular reporting obligations under SEC rules. For comprehensive data on NRXP, BRPA, and thousands of other SPAC transactions, create a free account on SpacDesk.